Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
百时美施贵宝（纽交所：BMY）今天宣布，欧盟委员会（EC）已批准Opdivo（尼伏单抗）联合Yervoy（伊匹木单抗）用于治疗成人微卫星不稳定性高（MSI-H）或错配修复缺陷（dMMR）不可手术切除或转移性结直肠癌（mCRC）的首选治疗。
"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "The EC's decision to approve Opdivo plus Yervoy represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."
"结直肠癌是欧洲第二大癌症死亡原因，患者需要新的治疗选择来延缓疾病进展。大约5-7%的转移性结直肠癌患者有MSI-H/dMMR肿瘤，而这些患者从常规化疗中获益的可能性较小，通常预后较差，" 达纳·沃克万.D.万.S.C.E.，百时美施贵宝Opdivo全球项目负责人、副总裁表示，"欧盟委员会批准Opdivo联合Yervoy的决定对于这一患者群体来说是一个重要的里程碑，强调了我们致力于推进治疗选择的承诺。"
